链球菌制剂OK-432可抑制MRL/Mp-lpr/lpr小鼠的自身免疫性肾病。
Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.
作者信息
Mihara M, Ohsugi Y
机构信息
Section of Immunopharmacology, Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Company, Shizuoka, Japan.
出版信息
Clin Exp Immunol. 1989 Oct;78(1):102-7.
Autoimmune MRL/Mp-lpr/lpr (MRL/l) mice were treated with the immunostimulating anti-cancer drug OK-432 (a streptococcal preparation), a potent inducer of tumour necrosis factor. Treatment was initiated at 8 weeks of age, before the onset of the autoimmune disease. OK-432 prevented the development of immune complex-mediated glomerulonephritis in a dose-dependent manner, and prolonged the life in this strain of mice. At 36 weeks of age, the incidence of proteinuria was 90% in the controls, 60% in the 0.5-KE(1 KE = 0.1 mg) treatment group, and 33% in the 2.0-KE group. The 50% survival time was 23 weeks for the controls; 32 weeks for the 0.5-KE group; and greater than 36 weeks for the 2.0-KE group. Immune complex deposition in glomeruli was significantly reduced in the treated groups. The IgM class of serum autoantibody levels was significantly increased by OK-432 treatment but the IgG class was almost unchanged. Furthermore, lymphadenopathy and splenomegaly were not suppressed. The results indicate that OK-432 may be useful in the treatment of autoimmune disease in humans.
将自身免疫性MRL/Mp-lpr/lpr（MRL/l）小鼠用免疫刺激抗癌药物OK-432（一种链球菌制剂，肿瘤坏死因子的强效诱导剂）进行治疗。治疗在8周龄时开始，即在自身免疫性疾病发作之前。OK-432以剂量依赖的方式预防了免疫复合物介导的肾小球肾炎的发展，并延长了该品系小鼠的寿命。在36周龄时，对照组蛋白尿的发生率为90%，0.5KE（1KE = 0.1mg）治疗组为60%，2.0KE组为33%。对照组的50%生存时间为23周；0.5KE组为32周；2.0KE组大于36周。治疗组肾小球中的免疫复合物沉积明显减少。OK-432治疗使血清自身抗体IgM类水平显著升高，但IgG类几乎未变。此外，淋巴结病和脾肿大未受到抑制。结果表明OK-432可能对人类自身免疫性疾病的治疗有用。
Zotero 插件